Details of the Drug Combination

General Information of Drug Combination (ID: DC6GXE8)

Drug Combination Name
Cefmenoxime Cisatracurium
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Cefmenoxime   DMPLY7B Cisatracurium   DMUZPJ5
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 11.99
Bliss Independence Score: 11.99
Loewe Additivity Score: 24.52
LHighest Single Agent (HSA) Score: 24.52

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cefmenoxime
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [2]
Cefmenoxime Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein 3 (Bact mrcA) TT85JMW FTSI_ECOLI Binder [4]
------------------------------------------------------------------------------------
Indication(s) of Cisatracurium
Disease Entry ICD 11 Status REF
Muscle spasm MB47.3 Approved [3]
Cisatracurium Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cholinergic receptor unspecific (CHR) TTUPDWN NOUNIPROTAC Antagonist [5]
Neuronal acetylcholine receptor alpha-2 (CHRNA2) TTF4E0J ACHA2_HUMAN Antagonist [6]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701.
5 Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
6 Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.